KRAS and cancer: Based on their findings, there were 1550 mutations that could be found in at least five patients, including KRAS G12V (5.8%), KRAS G12D (8%), PIK3CA E545K (3.5%), BMPR2 N583Tfs44 (2.8%), and PIK3CA H1047R (2.5%), with higher mutation rates in metastatic pan-cancers, indicating as possible targets for cancer immunotherapy [138].